Product image of Mozobil (Plerixafor) supplied by GNH India

Mozobil

Active Ingredient:
Plerixafor
Origin:
EU

Mozobil (Plerixafor)

Plerixafor, the active ingredient in Mozobil, is a CXCR4 antagonist presented as a 0.24 mg/mL injection solution for subcutaneous use. It facilitates the mobilization of hematopoietic stem cells into peripheral blood, enabling autologous transplantation in patients with non‑Hodgkin lymphoma and multiple myeloma.

GNH India supplies Mozobil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sanofi B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mozobil (plerixafor) is employed to mobilize hematopoietic stem cells in hematologic malignancies.

  • Non‑Hodgkin lymphoma: enhances peripheral blood stem cell collection for autologous transplantation.
  • Multiple myeloma: promotes stem cell release to support autologous transplant procedures.
  • Other eligible hematologic cancers: enables stem cell harvesting for autologous transplant as determined by the treating physician.

How It Works

  • Plerixafor antagonizes the CXCR4 receptor, disrupting its interaction with stromal cell‑derived factor‑1 (SDF‑1). This blockade releases hematopoietic stem cells from the bone‑marrow niche into the peripheral circulation, increasing the number of collectable stem cells for autologous transplantation in eligible patients.

Side Effects

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Injection site reactions: redness, swelling, or pain at the subcutaneous site.
  • Diarrhea: loose stools occurring shortly after administration.
  • Fatigue: transient tiredness reported by some patients.
  • Headache: mild to moderate intensity.
  • Dizziness: occasional sensation of light‑headedness.

Serious or Rare Side Effects

  • Severe allergic reaction (anaphylaxis): rapid onset of breathing difficulty, swelling, or rash.
  • Splenic rupture: rare but potentially life‑threatening abdominal pain.
  • Severe hypotension: marked drop in blood pressure requiring medical attention.
  • Acute leukocytosis: sudden increase in white blood cell count.

Precautions & Warnings

Before using Mozobil, clinicians should consider several safety measures.

  • Assess eligibility: confirm that autologous stem cell mobilization is indicated for the patient.
  • Monitor blood counts: observe hematologic parameters before and after administration.
  • Evaluate hypersensitivity: check for known allergy to plerixafor or formulation components.
  • Cardiovascular caution: avoid in patients with uncontrolled hypertension or severe cardiac disease.
  • Use in experienced centers: administer under supervision of a transplant‑qualified team.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Plerixafor may interact with other agents that affect stem cell mobilization or immune function.

Major Interactions (Avoid)

  • Concurrent CXCR4 antagonists: may lead to excessive stem cell release.
  • Unsupervised combination with high‑dose chemotherapy: increases risk of severe toxicity.
  • Use with investigational agents targeting SDF‑1/CXCR4 pathway without guidance.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: monitor for bleeding tendencies.
  • Antihistamines: may mask early signs of allergic reactions.
  • Other immunomodulators: observe for altered immune response.

Frequently Asked Questions

Mozobil (plerixafor) is used to mobilize hematopoietic stem cells from the bone marrow into the peripheral blood, facilitating collection for autologous transplantation in patients with non‑Hodgkin lymphoma or multiple myeloma.

Plerixafor blocks the CXCR4 receptor, preventing its binding to stromal cell‑derived factor‑1 (SDF‑1). This disruption releases stem cells from their marrow niche, increasing their numbers in the bloodstream for collection.

The dose of Mozobil is individualized by the prescribing physician based on the patient’s weight, disease status, and stem cell collection protocol. Exact dosing regimens are not publicly disclosed.

The safety of Mozobil in pregnancy or while breastfeeding has not been established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant.

To order Mozobil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Mozobil is a CXCR4 antagonist, whereas other mobilizers such as G‑CSF act via different pathways. Clinical studies show that plerixafor can increase stem cell yields, especially in patients who respond poorly to G‑CSF alone, but the choice depends on individual patient factors and transplant centre protocols.

Mozobil should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

Mozobil is supplied as a sterile injection solution for subcutaneous administration. It is typically injected under the skin by a qualified healthcare professional according to the transplant centre’s protocol.

Serious risks include severe allergic reactions (anaphylaxis), splenic rupture, marked hypotension, and acute leukocytosis. Patients should be monitored closely for these events, especially during and after the injection.

Mozobil should not be used in patients with known hypersensitivity to plerixafor or any excipients, in those with uncontrolled cardiovascular disease, or in individuals where stem cell mobilization is not indicated. Use is also contraindicated without supervision by an experienced transplant team.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Plerixafor

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT